Psychedelics are having a moment in psychiatry, and for good reason. Research on substances like psilocybin, MDMA, and ketamine has shown promising results for treatment-resistant depression, PTSD, and other mental health conditions. The FDA has already approved esketamine (Spravato™) for depression, and clinical trials for MDMA-assisted therapy for PTSD are in late stages. The excitement is real—but so is the need for nuance.
Here’s the reality: psychedelics aren’t a magic bullet. While they can be powerful tools, they don’t “cure” mental illness. Their real potential lies in how they’re used. Psychedelic-assisted therapy (PAT) is where these treatments shine—helping patients process emotions, reframe experiences, and make meaningful changes. Simply taking the drug without a therapeutic framework is like getting surgery without rehab; you might get some benefits, but you’re missing the full picture.
I recognize the value these treatments can bring, but I also believe in using them responsibly. If patients are considering ketamine treatment, I can refer to reputable clinics for Spravato™ or IV ketamine infusions, ensuring they have access to evidence-based care in a safe and structured environment.